New HIV drug shows promise for safer pregnancies

NCT ID NCT02245022

Completed Disease control Sponsor: University of Liverpool Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether the HIV drug dolutegravir is safe and effective in pregnant women who have not yet been treated for HIV. Sixty women in late pregnancy were randomly assigned to receive either dolutegravir or standard HIV medicines. The goal was to measure drug levels in the mother and check for side effects, with the hope of reducing the chance of passing HIV to the baby.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dolutegravir (Tivicay)
What this could lead to: If successful, this could point toward a safer, more effective way to prevent HIV transmission from mother to baby during pregnancy and delivery.
What could go wrong: This is a small pilot study focused on drug levels, not large-scale proof of effectiveness. Results may not apply to all populations, and side effects in pregnancy are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Feeding HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREGNANCY

Contacts and locations

Locations

Desmond Tutu HIV Foundation

Cape Town, Western Cape, South Africa
Infectious Diseases Institute

Kampala, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.